Table 3.
Cost-effectiveness model attributes, funding, and CHEERS criteria.
| Author | Year | Full study or letter to the editor | Comparators | Health outcomes | Choice of model | Probabilistic Sensitivity Analysis | Funding Source | CHEERS Criteria Percentage |
|---|---|---|---|---|---|---|---|---|
| Carpenter CF, et al. | 2019 | Full | RZV, ZVL, or no vaccine | costs and QALYs | Markov | Yes | No extramural funding | 100.0% |
| Curran D, et al. | 2019 | Full | RZV, revaccination with ZVL, or no further vaccination | shingles cases averted, deaths, costs, life years, and QALYs | Markov | Yes | GlaxoSmithKline | 96.0% |
| Prosser LA, et al. | 2019 | Full | RZV, ZVL, or no vaccine | costs and QALYs | Markov | Yes | Centers for Disease and Control | 100.0% |
| Curran D, et al. | 2018 | Full | RZV, ZVL, or no vaccine | shingles cases averted, deaths, costs, life years, and QALYs | Markov | Yes | GlaxoSmithKline | 96.0% |
| Dooling KL, et al. | 2018 | Full | RZV, ZVL, or no vaccine | costs and QALYs | Not stated | Yes | No extramural funding | 41.7% |
| Le P and Rothberg MB | 2018 | Full | RZV, ZVL, or no vaccine | costs and QALYs | Markov | Yes | No extramural funding | 100.0% |
| Le P and Rothberg MB | 2018 | Letter | RZV, ZVL, ZVL with RZV, or no vaccine | costs and QALYs | Markov | Yes | No extramural funding | 100.0% |
QALY = quality-adjusted life year, RZV = recombinant zoster vaccine, ZVL = zoster vaccine live.